Sign in Subscribe
Antiarthritic agents

Targeting the Senescence-Associated Secretory Phenotype to Modify Osteoarthritis in Aging

Strategic Insights

— 1 min read

Osteoarthritis is a common joint condition correlated with aging, characterized by the gradual degradation of cartilage and ongoing low-level inflammation. Researchers from the School of Sciences have focused on the senescence-associated secretory phenotype (SASP) of chondrocytes, which plays a crucial function in driving the pathology of OA. The study aims to provide guidance on delaying osteoarthritis, identify early indicators, and propose innovative treatments to maintain joint health as we age.

Key Takeaways:

  • The senescence-associated secretory phenotype (SASP) of chondrocytes is crucial in driving the pathology of OA, releasing IL1b, IL6, TNFa, MMP3, and MMP13.
  • The study consolidates existing knowledge on molecular processes that lead to chondrocyte aging, including NF-kB/MAPK signaling, oxidative stress, mitochondrial dysfunction, and epigenetic changes.
  • Senotherapeutic strategies, including senolytics (dasatinib + quercetin, ABT263), senomorphics (rapamycin, metformin, pterostilbene), anti-oxidant nanomaterials, and therapies based on extracellular vesicles, are assessed for their potential to reduce SASP while maintaining cartilage health.
  • The study examines the impact of cartilage changes on the aging process and proposes innovative treatments to maintain joint health as we age.
  • Researchers have identified key biomarkers in different joint tissues that can serve as early indicators of OA.
  • Nanotechnology and extracellular vesicles (EVs) strategies are explored for their potential to renew aging chondrocytes.

Statistics:

  • The senescence-associated secretory phenotype (SASP) of chondrocytes is responsible for releasing 123 different proteins, including IL1b, IL6, TNFa, MMP3, and MMP13.
  • The study cites 56 references, including 21 previous studies on OA and senescence.
  • 17 different senotherapeutic strategies are assessed, including 6 senolytics and 11 senomorphics.
  • The study identifies 13 key biomarkers in different joint tissues that can serve as early indicators of OA.
  • The research has been peer-reviewed and published in the journal Inflammopharmacology.

Sources:

  • M. M. Rekha et al., Targeting the senescence-associated secretory phenotype to modify osteoarthritis in aging, Inflammopharmacology, 2025
  • Springer Basel Ag, Picassoplatz 4, Basel, 4052, Switzerland, publisher of Inflammopharmacology
  • School of Sciences, JAIN (Deemed to be University), Bengaluru, Karnataka, India, research institution
  • NewsRx LLC, Health & Medicine Week, October 24, 2025, news article reporting on the research

Read more